Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain inhibitors, which have shown efficacy in several models of cancer(4-6), have not been evaluated in TNBC. These inhibitors displace BET bromodomain pr...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:Nature
প্রধান লেখক: Shu, Shaokun, Lin, Charles Y., He, Housheng Hansen, Witwicki, Robert M., Tabassum, Doris P., Roberts, Justin M., Janiszewska, Michalina, Huh, Sung Jin, Liang, Yi, Ryan, Jeremy, Doherty, Ernest, Mohammed, Hisham, Guo, Hao, Stover, Daniel G., Ekram, Muhammad B., Brown, Jonathan, D'Santos, Clive, Krop, Ian E., Dillon, Deborah, McKeown, Michael, Ott, Christopher, Qi, Jun, Ni, Min, Rao, Prakash K., Duarte, Melissa, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Anders, Lars, Young, Richard A., Winer, Eric, Letai, Antony, Barry, William T., Carroll, Jason S., Long, Henry, Brown, Myles, Liu, X. Shirley, Meyer, Clifford A., Bradner, James E., Polyak, Kornelia
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: 2016
বিষয়গুলি:
Article
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854653/
https://ncbi.nlm.nih.gov/pubmed/26735014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature16508
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি